Peter Yeh, MD
Orthopaedic Surgery · Woburn, MANPI 1942482237
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (31.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. Arthrex accounts for 73.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $12,145 and has fallen 88.8% since, to $1,358 in 2025.
Across 134 payments — averaging $281.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$28K
- Kairos Surgical Inc$9K
- Stryker$409
- Smith+Nephew$106
- Abbott$69
- Pacira Pharmaceuticals Incorporated$64
- plus $367 from 12 others
What the payments were for
- Consulting fees$6,00016%
- Speaking & faculty fees$11,82531%
- Travel & lodging$8,65923%
- Food & beverage$3,4899%
- Education$7,75421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 76 | $27,679 |
| Kairos Surgical Inc | 30 | $9,033 |
| Stryker | 7 | $409 |
| Smith+Nephew | 3 | $106 |
| Abbott | 1 | $69 |
| Pacira Pharmaceuticals Incorporated | 3 | $64 |
| Medtronic | 1 | $58 |
| Vericel Corporation | 1 | $42 |
| Orthofix Medical, Inc. | 2 | $40 |
| Miach Orthopaedics, Inc. | 1 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Vertex | 1 | $30 |
| Acera Surgical, Inc. | 1 | $26 |
| Arteriocyte Medical Systems, Inc. | 1 | $26 |
| Convatec Inc. | 1 | $20 |
| Linvatec Corporation | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,727 in reported general payments places this provider in the 85th percentile of 542 orthopaedic surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 17 | $150 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Woburn
- Paul TornettaBoston$16.3M
- Thomas ThornhillBoston$12M
- Stephen MurphyRoxbury Crossing$8M
- Andrew FreibergBoston$5.9M
- Jon WarnerBoston$5.4M
- Wolfgang FitzBoston$3.7M
- Brian KwonWaltham$1.9M
- Simon ChaoNorth Easton$1.6M
- Scott SigmanNorth Chelmsford$1.4M
- Michael LangworthyNorth Dartmouth$715K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.